Drugs /

sv-br-1-gm

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.

Clinical Trials

View Clinical Trials for sv-br-1-gm

Sv-br-1-gm has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating sv-br-1-gm, 2 are phase 1/phase 2 (1 open).

HLA-A*24:02 Positive, HLA-B*35:08, and HLA-B*55:01 are the most frequent biomarker inclusion criteria for sv-br-1-gm clinical trials.

Breast carcinoma is the most common disease being investigated in sv-br-1-gm clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sv-Br-1-Gm
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sv-Br-1-Gm
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sv-br-1-gm and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
allogeneic gm-csf-secreting breast cancer vaccine sv-br-1-gm, breast cancer vaccine sv-br-1-gm, gm-csf gene-transfected breast cancer vaccine sv-br-1-gm, sv-br-1-gm vaccine, bria-imt, sv-br-1 breast cancer cell line vaccine
NCIT ID [1]:
C146711

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.